Genome sequencing in prenatal precision medicine of congenital malformations: Clinical experience from a single center

INTRODUCTION: As a part of implementing genome sequencing in prenatal precision medicine at the department of Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden, we evaluated the utility of genome sequencing for prenatally detected malformations, including diagnostic yield, turnaround time and impact on current and future pregnancies. MATERIAL AND METHODS: This study comprised 218 fetuses with different malformations. One hundred and two prospectively collected samples were analyzed using clinical trio genome sequencing, and if non-diagnostic, they underwent research analysis. In addition, 116 samples were collected retrospectively and included all fetuses referred for clinical trio genome sequencing during the study period. As part of the clinical routine at the time of the study, quantitative fluorescent-polymerase chain reaction and chromosomal microarray had been performed before genome sequencing in 84.9% (185/218) of cases. RESULTS: Clinical genome sequencing identified a molecular diagnosis in 22.5% (49/218) of the cases. Research analysis revealed two additional causative variants increasing the diagnostic yield to 23.4% (51/218). The phenotypes of the cases were divided into different groups with following diagnostic yields: 36.2% (21/58) in multisystem malformations, 30.8% (8/26) in skeletal malformations, 25.0% (14/56) in malformations in the central nervous system, 15.6% (5/32) in thoracic malformations, 11.5% (3/26) in abdominal malformations, and 0% (0/20) in other isolated anomalies. Additionally, four variants were considered potentially clinically relevant. A total of 39.2% (20/51) of the causative variants were related to a risk of recurrence. The turnaround time for clinical genome sequencing in ongoing pregnancies, when requested before gestational week 21 + 6 and prior to a parental decision on pregnancy continuation, was 12.5 ± 5 days (mean ± standard deviation, n = 40). Pregnancies with diagnostic results from genome sequencing were more likely to be terminated than those with normal results (p = 0.012, Fisher's exact test). CONCLUSIONS: Genome sequencing has an important role in prenatal precision medicine, since it can detect the underlying cause of prenatally detected malformations in a reasonable time. As causative chromosome aberrations were excluded in most of the cases, an even higher diagnostic yield can be expected if genome sequencing is offered as a first-line test or after a normal rapid aneuploidy detection result.

Authors

Institutions

Publication Details

Journal
Acta Obstetricia Et Gynecologica Scandinavica
Published
2026-11-13
DOI
https://doi.org/10.1111/aogs.70381
Primary Topic
Prenatal Screening and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genome sequencing in prenatal precision medicine of congenital malformations: Clinical experience from a single center

Erik Iwarsson, Peter Conner, Meeli Sirotkina, Nikos Papadogiannakis et al.
5 links
Acta Obstetricia Et Gynecologica Scandinavica
Prenatal Screening and Diagnostics
article

Genome sequencing in prenatal precision medicine of congenital malformations: Clinical experience from a single center

Erik Iwarsson, Peter Conner, Meeli Sirotkina, Nikos Papadogiannakis, Maria Pettersson, Eini Westenius, Ellika Sahlin, Hafdis Th. Helgadottir, Anna Lindstrand
article en

Abstract

INTRODUCTION: As a part of implementing genome sequencing in prenatal precision medicine at the department of Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden, we evaluated the utility of genome sequencing for prenatally detected malformations, including diagnostic yield, turnaround time and impact on current and future pregnancies. MATERIAL AND METHODS: This study comprised 218 fetuses with different malformations. One hundred and two prospectively collected samples were analyzed using clinical trio genome sequencing, and if non-diagnostic, they underwent research analysis. In addition, 116 samples were collected retrospectively and included all fetuses referred for clinical trio genome sequencing during the study period. As part of the clinical routine at the time of the study, quantitative fluorescent-polymerase chain reaction and chromosomal microarray had been performed before genome sequencing in 84.9% (185/218) of cases. RESULTS: Clinical genome sequencing identified a molecular diagnosis in 22.5% (49/218) of the cases. Research analysis revealed two additional causative variants increasing the diagnostic yield to 23.4% (51/218). The phenotypes of the cases were divided into different groups with following diagnostic yields: 36.2% (21/58) in multisystem malformations, 30.8% (8/26) in skeletal malformations, 25.0% (14/56) in malformations in the central nervous system, 15.6% (5/32) in thoracic malformations, 11.5% (3/26) in abdominal malformations, and 0% (0/20) in other isolated anomalies. Additionally, four variants were considered potentially clinically relevant. A total of 39.2% (20/51) of the causative variants were related to a risk of recurrence. The turnaround time for clinical genome sequencing in ongoing pregnancies, when requested before gestational week 21 + 6 and prior to a parental decision on pregnancy continuation, was 12.5 ± 5 days (mean ± standard deviation, n = 40). Pregnancies with diagnostic results from genome sequencing were more likely to be terminated than those with normal results (p = 0.012, Fisher's exact test). CONCLUSIONS: Genome sequencing has an important role in prenatal precision medicine, since it can detect the underlying cause of prenatally detected malformations in a reasonable time. As causative chromosome aberrations were excluded in most of the cases, an even higher diagnostic yield can be expected if genome sequencing is offered as a first-line test or after a normal rapid aneuploidy detection result.

Acta Obstetricia Et Gynecologica Scandinavica
Karolinska University Hospital (SE), Karolinska Institutet (SE)
Hjärnfonden, Karolinska Institutet, Vetenskapsrådet, Stockholm läns landsting
Good health and well-being
Prenatal Screening and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon